Multicenter Evaluation of a New Electrochemiluminescence Immunoassay for Everolimus Concentrations in Whole Blood
Conclusions: Based on these results, the Roche Elecsys everolimus ECLIA can be considered suitable for routine therapeutic drug monitoring. A positive bias was observed with respect to LC-MS/MS methods, suggesting that it may be necessary to rebaseline individual patients when switching from LC-MS/MS to the ECLIA; however, this must also be considered for any change of method for everolimus measurement.
Authors: Mankahla N, Dlamini S, Taunyane IC, Maqungo S, Cairncross L, Chiliza B PMID: 30004352 [PubMed - in process]
Authors: Franco A, Balibrea N, Gimeno A, Merino E, Lopez MI, Santiago C, Perez Contreras F PMID: 30006233 [PubMed - as supplied by publisher]
We presently forget 98% of everything we experience. That will go away in favor of perfect, controllable, configurable memory. Skills and knowledge will become commodities that can be purchased and installed. We will be able to feel exactly as we wish to feel at any given time. How we perceive the world will be mutable and subject to choice. How we think, the very fundamental basis of the mind, will also be mutable and subject to choice. We will merge with our machines, as Kurzweil puts it. The boundary between mind and computing device, between the individual and his or her tools, will blur. Over the course of the ...
Authors: Heidt S, Claas FHJ Abstract INTRODUCTION: Highly sensitized patients awaiting a kidney transplant accrue on the transplant waiting list. The breadth of HLA antibodies in this subpopulation of patients precludes receiving a compatible organ offer through regular allocation within an acceptable time-frame. Areas covered: Several alternative options to receive a transplant exist for these patients, including additional priority in regular allocation, special programs based on allocation through acceptable antigens, kidney paired donation programs, desensitization protocols, or a combination of the latter two....
Authors: Malyszko J, Dryl-Rydzynska T, Marcinkowski W, Prystacki T, Malyszko JS PMID: 30002713 [PubMed]
Angiotensin II (Ang II) infusion promotes the development of aortic aneurysms and accelerates atherosclerosis in ApoE −/− mice. In order to elucidate the role of hematopoietic cells in these pathologies, irradiation and bone marrow transplantation (BMT) are commonly utilized. The aim of this study was to investigate the effects of irradiation and BMT on abdominal and thoracic aortic aneurysm formation and acute leukocyte recruitment in the aortic root and descending aorta, an experimental mouse model of aortic aneurysm formation.
It has been 5 years since the last update on infections in solid organ transplant (SOT) recipients was published in Infectious Diseases Clinics of North America in 2013. There has been a 20% increase in the number of organ transplants over the last 5 years,1 largely driven by increase in the number of deceased donors, with more than 33,000 transplants performed annually in the United States. Our nation is facing an unprecedented opioid epidemic, which is currently accounting in several parts of the country for a quarter of organ donors who die of overdose.
The PD-1/PD-L1 (programmed cell death) pathway is an immune checkpoint, which protects normal tissues but can also prevent anti-tumor immune response. The FDA approvals of checkpoint inhibitors constitutes a major advance in the immunotherapy of cancer . Chronic myeloid leukemia (CML) is an example of successful use of tyrosine kinase inhibitors (TKIs). Blockade of oncogenic BCR-ABL1 kinase activity translated into an impressive control of the disease. CML is also known to be responsive to immunotherapy and long-term eradication of CML has been achieved by allogeneic hematopoietic stem cell transplantation .
In this issue of Biology of Blood and Marrow Transplantation, Coomes and colleagues report results in a cohort of allogeneic transplant recipients treated at the Princess Margaret Cancer Centre for severe BK polyoma virus-caused hemorrhagic cystitis (HC) with intravenous and/or intravesical cidofovir.1 HC following allogeneic hematopoietic cell transplantation is a challenging clinical problem as the treatment options are often ineffective and the potential complications and associated morbidities for the patient can be severe.
Curative therapies can leave a lasting burden on cancer patients. Survivorship issues are becoming a "pandemic of treatment success" and include not only short- and long-term treatment sideeffects, development of subsequent cancers, and psychosocial issues, but also a lasting financial toll. It is increasingly recognized that cancer survivorship is tightly associated with a decline in financial health and the unavoidable impact of high associated medical care costs extending beyond those accrued during the initial treatment.